Tomorrow will be an interesting day for Roche (NASDAQOTH: RHHBY )
, its shareholders, and those interested in the treatment of
Alzheimer's disease (or AD). Roche is scheduled to report phase 2 data
on its antibody therapy crenezumab in patients with mild and moderate
Alzheimer's. It is wise to expect little from any experimental AD, as
this disease has frustrated almost every company that has attempted to
develop a therapy, but the potential of a successful drug is so high
that any credible attempt is at least worth watching.
Continue here:
Can Roche Find Rare Success In Alzheimer's?
No comments:
Post a Comment